Americas Insomnia Market Analysis
Americas Insomnia Market Research Report, by types of therapy (Pharmacological therapy and Non Pharmacological therapy), by drug formulation (Capsules, Tablet and others), by type of disease (poor quality of sleep, sleep maintenance and others)- Forecast till 2035

Market Summary
The United States insomnia market is projected to grow from 2.43 USD billion in 2024 to 4.12 USD billion by 2035.
Key Market Trends & Highlights
Americas Insomnia Key Trends and Highlights
- The insomnia market in the United States is expected to experience a compound annual growth rate of 5.34 percent from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 4.31 USD billion, indicating robust growth potential.
- in 2024, the market is valued at 2.43 USD billion, reflecting the current demand for insomnia solutions.
- Growing adoption of innovative sleep therapies due to increasing awareness of mental health is a major market driver.
Market Size & Forecast
2024 Market Size | 2.43 (USD Billion) |
2035 Market Size | 4.12 (USD Billion) |
CAGR (2025-2035) | 4.92% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), Vanda Pharmaceuticals Inc. (US)
Market Trends
Americas Insomnia Market Market Drivers
Market Segment Insights
Regional Insights
Key Companies in the Americas Insomnia Market market include







Industry Developments
Market Segmentation
Report Scope
Attribute/Metric | Details |
Market Size 2024 | USD 2.43 billion |
Market Size 2035 | 4.12 (Value (USD Billion)) |
Compound Annual Growth Rate (CAGR) | 4.92% (2025 - 2035) |
Base Year | 2024 |
Market Forecast Period | 2025 - 2035 |
Historical Data | 2019- 2021 |
Market Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Growth Factors, Market Competitive Landscape, and Trends |
Segments Covered | Types Of Therapy, Drug Formulation, Type Of Diseases Condition and Region |
Geographies Covered | North America |
Countries Covered | U.S, Canada |
Key Companies Profiled | Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US). |
Key Market Opportunities | Increasing awareness of sleep disorders, and changing lifestyle patterns |
Key Market Dynamics | Increasing prevalence of insomnia among the population |
Market Size 2025 | 2.55 (Value (USD Billion)) |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
-
Table of Contents
-
1 INTRODUCTION
- DEFINITION
-
SCOPE OF STUDY
- RESEARCH OBJECTIVE
- ASSUMPTIONS & LIMITATIONS
- MARKET STRUCTURE:
-
2 Research Methodology
- RESEARCH PROCESS:
- PRIMARY RESEARCH
- SECONDARY RESEARCH:
-
3 MARKET DYNAMICS
- DRIVERS
- RESTRAINTS
- OPPORTUNITIES
- MACROECONOMIC INDICATORS
-
4 MARKET FACTOR ANALYSIS
- PORTERS FIVE FORCES MODEL
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF BUYERS
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTES
- INTENSITY OF RIVALRY
-
AMERICAS INSOMNIA MARKET, BY TYPES OF THERAPY
-
PHARMACOLOGICAL THERAPY
- BENZODIAZEPINES
- NON-BENZODIAZEPINES
- MELATONIN RECEPTOR AGONISTS
- OTHER
-
NON PHARMACOLOGICAL THERAPY
- RELAXATION THERAPY
- COGNITIVE BEHAVIORAL THERAPY
- SLEEP HYGIENE EDUCATION
- STIMULUS CONTRO
- PARADOXICAL INTENTION
- OTHER
-
PHARMACOLOGICAL THERAPY
-
AMERICAS INSOMNIA MARKET, BY DRUG FORMULATION
- CAPSULES
- TABLET
- OTHERS.
-
AMERICAS INSOMNIA MARKET, BY TYPES OF DISEASE
- POOR QUALITY OF SLEEP
- SLEEP MAINTENANCE
- OTHER.
-
AMERICAS INSOMNIA MARKET, BY REGION
- INTRODUCTION
-
NORTH AMERICA
- US
- Canada
- SOUTH AMERICA
-
Competitive Landscape
-
MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
- STRATEGIC PARTNERSHIP
- MERGER & ACQUISITION
-
MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
-
10 COMPANY PROFILE
-
EISAI, CO.
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
MERCK & CO INC
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
SANOFI
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- STRATEGY
- KEY DEVELOPMENT
-
TAKEDA PHARMACEUTICAL COMPANY
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
PFIZER, INC.
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
- OTHERS
-
EISAI, CO.
Americas Insomnia Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment